|
Getting your Trinity Audio player ready...
|
A number of actively traded small-cap and growth stocks are drawing increased investor attention as momentum continues building across sectors tied to AI infrastructure, biotechnology, GLP-1 healthcare, vaccines, high-performance computing, and digital infrastructure. Names currently trading actively include ENDRA Life Sciences Inc. (NASDAQ: NDRA), Sunshine Biopharma Inc. (NASDAQ: SBFM), GeoVax Labs Inc. (NASDAQ: GOVX), HIVE Digital Technologies Ltd. (NASDAQ: HIVE), and Sphere 3D Corp. (NASDAQ: ANY).
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is drawing increasing investor attention after reporting strong multi-site validation results for its TAEUS® Liver imaging platform, demonstrating MRI-level agreement in measuring liver fat for steatotic liver disease (SLD) and metabolic dysfunction–associated steatohepatitis (MASH), rapidly growing healthcare markets tied to the GLP-1 therapy boom. The company also recently reported first quarter 2026 results showing reduced cash used in operations compared to the prior year, reflecting disciplined execution as it advances commercialization efforts. ENDRA’s Board has additionally initiated a strategic review process aimed at maximizing shareholder value, adding further interest around the company’s future direction as investors monitor NDRA as a potential diagnostic infrastructure play within one of healthcare’s fastest-growing sectors.
Meanwhile, Sunshine Biopharma Inc. (NASDAQ: SBFM) continues expanding its pharmaceutical footprint with 71 marketed generic prescription drugs in Canada and 12 additional launches planned through the remainder of 2026. The company is also advancing proprietary therapeutic programs, including K1.1 mRNA, an mRNA-Lipid Nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor focused on SARS-related coronavirus infections, positioning SBFM within both oncology and antiviral development markets.
In the vaccine and immunotherapy sector, GeoVax Labs Inc. (NASDAQ: GOVX) is drawing attention following a recent Zacks Rank #2 (Buy) upgrade. GeoVax is advancing GEO-MVA, its Modified Vaccinia Ankara vaccine candidate targeting mpox and smallpox, while also progressing immuno-oncology initiatives centered around Gedeptin®. The company continues preparing for a planned Phase 3 immunobridging study aligned with guidance from the European Medicines Agency (EMA), potentially supporting an accelerated regulatory pathway and commercialization opportunity.
AI infrastructure and high-performance computing themes continue gaining momentum around HIVE Digital Technologies Ltd. (NASDAQ: HIVE), which recently announced plans through BUZZ High Performance Computing Inc. to advance a 320 MW AI gigafactory project in the Greater Toronto Area. The facility is expected to support more than 100,000 GPUs at full build-out and could become one of Canada’s largest sovereign AI infrastructure platforms, targeting enterprise AI, supercomputing, and next-generation compute workloads.
At the same time, momentum continues building around Sphere 3D Corp. (NASDAQ: ANY) as investors increasingly focus on the company’s transition from a traditional bitcoin mining operator into an emerging AI infrastructure and power-backed data center platform. Shares recently closed at a 30-day high of $2.43 on elevated volume as the market responds to the company’s growing exposure to AI infrastructure, GPU compute, high-performance computing (HPC), and energy-backed digital infrastructure trends.
As capital continues rotating into AI infrastructure, GLP-1 healthcare, biotech innovation, vaccines, and next-generation computing, traders are closely monitoring these actively traded stocks for continued momentum and sector-driven upside potential.